July 20, 2017
…equipped with a special receptor that recognizes and targets cancer stem cells, whose survival abilities often render standard therapies ineffective or short-term.
December 4, 2018
In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs.
November 1, 2022
Researchers at UC San Diego School of Medicine and Moores Cancer Center at UC San Diego Health describe the first preclinical model of appendiceal cancer that contains all elements of the tumor, allowing previously stymied investigations to proceed.
August 21, 2019
University of California San Diego School of Medicine researchers identified a new therapeutic approach in mouse models that halts drug resistance and cancer progression by using an antibody that induces the immune system via macrophages to seek and kill cancer cells.
April 2, 2015
…they are able to respond and become liver or pancreatic cells.
July 24, 2012
Sally Ride, professor emeritus of physics at the University of California, San Diego and former director of the University of California’s California Space Institute, died July 23 of pancreatic cancer. She was 61.
October 10, 2017
…diagnosis of stage IV pancreatic cancer and ongoing chemotherapy, Mike Levine boarded a plane this past weekend destined for Kona, Hawaii, where he will compete in one of the most grueling of physical competitions: the Ironman World Championship. Cheering him on will be his wife Jan, friends and Paul Fanta,…
November 21, 2017
…environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells are confined in a dense environment, the researchers found that they turn on a specific set of genes and begin to form structures that resemble blood vessels.
January 15, 2014
…invasive surgery (MIS) across the nation for patients with pancreatic disease. Although adaptation of MIS for this difficult-to-reach gland is recent, the growing trend points to improved patient outcomes, such as reduced bleeding and infections.
September 20, 2019
Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego researchers describe new use of leukemia drug, nilotinib, to treat subtype of medulloblastoma, a deadly pediatric brain cancer.
